31st Oct 2008 16:00
Vectura Group plc
Results of the Annual General Meeting held on 31 October 2008
Chippenham, UK, 31 October 2008: Vectura Group plc (LSE: VEC) announces that all resolutions proposed to shareholders at its Annual General Meeting held today were duly passed by shareholders.
All resolutions were approved on a poll. The results of the poll are set out below.
|
Resolution |
Total votes for (including discretionary votes)* |
% |
Total votes against* |
% |
Total votes cast (excluding votes withheld) |
Votes withheld |
|
|
1 |
To receive the Report & Accounts |
224,102,433
|
99.32
|
1,541,770
|
0.68
|
225,644,203
|
5,914
|
|
2 |
To re-elect Mr Jack Cashman |
223,548,883 |
99.24 |
1,711,806 |
0.76 |
225,260,689 |
389,428 |
|
3 |
To re-elect Ms Anne Hyland |
223,965,395 |
99.42 |
1,295,277 |
0.58 |
225,260,672 |
389,445 |
|
4 |
To re-appoint Deloitte & Touche LLP |
225,615,993 |
99.99 |
11,999 |
0.01 |
225,627,992 |
22,126 |
|
5 |
To approve the Report on Directors' Remuneration |
223,581,164 |
99.28 |
1,624,703 |
0.72 |
225,205,867 |
444,250 |
|
6 |
To renew the Directors' authority to allot shares |
225,529,791 |
99.96 |
91,171 |
0.04 |
225,620,962 |
29,156 |
|
7 |
To approve the amendments to the LTIP Rules |
219,854,305 |
99.26 |
1,631,563 |
0.74 |
221,485,868 |
4,164,078 |
|
8 |
To approve the terms of the VRP |
195,670,064 |
87.53 |
27,867,176 |
12.47 |
223,537,240 |
2,112,877 |
|
9 |
To renew the Directors' authority to allot shares on a non pre-emptive basis |
216,354,819 |
95.90 |
9,245,979 |
4.10 |
225,600,798 |
49,319 |
|
10 |
To adopt new Articles of Association |
176,289,935 |
80.97 |
41,431,150 |
19.03 |
217,721,085 |
7,505,914 |
*NB: The percentage of votes cast for and against excludes withheld votes.
Copies of the approved resolutions will be submitted to the UK Listing Authority and will shortly be available for inspection at the UK Listing Authority's Document Viewing facility, which is situated at:
Financial Services Authority
25 The North Colonnade
Canary Wharf
London E14 5HS
Tel: +44 (0)20 7676 1000
- Ends -
Enquiries:
Vectura Group plc - Tel: + 44 (0) 1249 667700
Chris Blackwell, Chief Executive
Anne Hyland, Chief Financial Officer
Julia Wilson, Director of Investor Relations
Financial Dynamics - Tel: + 44 (0) 207 831 3113
David Yates / Ben Atwell
Notes for Editors:
About Vectura
Vectura Group plc is a product development company focused on the development of a range of inhaled therapies principally for the treatment of respiratory diseases. Vectura develops products to treat respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis, a market which is forecast to double over the next ten years from $23 billion in 2007 to $46 billion by 2017. Vectura also develops products for non-respiratory diseases where optimised delivery via the lungs could provide significant benefits, such as a rapid onset of action, improved efficacy and improved tolerability compared with current therapies.
Vectura has eight products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development, some of which have been licensed to major pharmaceutical companies. The Company seeks to develop certain programmes further through development to optimise value through licensing at a later stage. Vectura also offers its formulation and inhalation technologies to other pharmaceutical companies on a licensing basis where this complements Vectura's business strategy.
Vectura has development collaborations with several pharmaceutical companies including Boehringer Ingelheim, Novartis and Sandoz (the generics arm of Novartis). The acquisition of Innovata in January 2007 brought established alliances with a number of additional companies, such as Baxter, GlaxoSmithKline (GSK), Merck Generics (part of Mylan Inc), UCB and Otsuka, as well as providing revenue streams, complementary products and critical mass. For further information, please visit Vectura's website at www.vectura.com
Related Shares:
VEC.L